Here are five key details:
- Dexamethasone is an inexpensive, on-the-shelf steroid used to treat conditions such as asthma, rheumatoid arthritis and certain cancers.
- The study, called RECOVERY, randomly prescribed 2,104 COVID-19 patients 6 milligrams of dexamethasone daily, which they took intravenously or by mouth. They were compared to 4,321 patients who received only standard care.
- Dexamethasone reduced the death rate by 35 percent in patients who needed to be on a ventilator and 20 percent in patients who needed oxygen but not a ventilator.
- The study did not find dexamethasone to be statistically beneficial in patients who did not require oxygen.
- The full study has yet to be published or face scientific scrutiny.
More articles on pharmacy:
FDA rescinds hydroxychloroquine emergency use authorization
10 exec moves affecting the pharma industry
U of Illinois to test Moderna’s COVID-19 vaccine in older and minority populations
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.